Management options for node-positive muscle-invasive bladder cancer.


Journal

Clinical advances in hematology & oncology : H&O
ISSN: 1543-0790
Titre abrégé: Clin Adv Hematol Oncol
Pays: United States
ID NLM: 101167661

Informations de publication

Date de publication:
Oct 2024
Historique:
medline: 2 10 2024
pubmed: 2 10 2024
entrez: 2 10 2024
Statut: ppublish

Résumé

Localized node-positive bladder cancer is characterized by a high degree of heterogeneity, leading to significant variability in overall survival outcomes among affected individuals. The absence of standardized treatment guidelines presents a critical challenge in managing these patients effectively. This comprehensive review article delves into the pathophysiology, clinical significance, and management of node-positive bladder cancer. It critically evaluates the current therapeutic landscape and explores emerging treatment strategies, including novel drugs currently undergoing clinical trials. By synthesizing the latest research findings, the review aims to provide valuable insights into the optimal management of node-positive urothelial cell carcinoma, ultimately contributing to improved patient outcomes and quality of life.

Identifiants

pubmed: 39356817

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

392-402

Auteurs

Hyma V Polimera (HV)

Department of Medicine, Division of Hematology-Oncology, Penn State Cancer Institute, Hershey, Pennsylvania.

Priyanka Bhatia (P)

Department of Medicine, Division of Hematology-Oncology, Penn State Cancer Institute, Hershey, Pennsylvania.

Megan Wheelden (M)

Department of Medicine, Division of Hematology-Oncology, Penn State Cancer Institute, Hershey, Pennsylvania.

Stuthi Perimbeti (S)

Department of Medicine, Division of Hematology-Oncology, Penn State Cancer Institute, Hershey, Pennsylvania.

Joshua Warrick (J)

Department of Pathology, Penn State Hershey Medical Center, Hershey, Pennsylvania.

Monika Joshi (M)

Department of Medicine, Division of Hematology-Oncology, Penn State Cancer Institute, Hershey, Pennsylvania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH